Affiliations of authors: M. Palmarini, Department of Medical Microbiology and Parasitology, College of Veterinary Medicine, University of Georgia, Athens; H. Fan, Cancer Research Institute and Department of Molecular Biology and Biochemistry, University of California, Irvine.
Correspondence to: Massimo Palmarini, D.V.M., Ph.D., Department of Medical Microbiology and Parasitology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602 (e-mail: mpalmari{at}vet.uga.edu).
![]() |
ABSTRACT |
---|
![]() |
INTRODUCTION |
---|
Ovine pulmonary adenocarcinoma (OPA)1 is a naturally occurring adenocarcinoma of sheep. It is interesting that, in a guest editorial that appeared in this Journal almost 20 years ago, Perk and Hod (10) concluded, "studies on OPA ... may aid in acquiring a better understanding of the pathogenesis, natural history, epidemiology, and host susceptibility of the disease and may lead to the selection of agents and modalities of chemotherapy in experimental animals and humans." In these intervening years, major advances have been made in understanding the pathogenesis of OPA and the biology of its causative agent. These breakthroughs have moved OPA from simply being an intriguing veterinary disease into a model system for lung cancer that is ripe for detailed studies at the molecular level.
This review will critically look at the data accumulated on OPA in the last decade, and it will put these results in the perspective of comparative pathology.
![]() |
OVINE PULMONARY ADENOCARCINOMA |
---|
OPA is transmitted as an infectious disease. The incidence of the disease is usually 2%5% (15,18,30,31), although in the U.K. it can be as high as 30%. In an affected flock, the disease can be responsible for more than 50% of the mortality (32). OPA generally affects young adult sheep. The diseased animals develop symptoms of progressive respiratory distress that worsen with increasing size of the lesions and resulting loss of alveolar function. Affected animals usually die within a few weeks of the onset of the clinical signs. A pathognomonic symptom of OPA is the accumulation of fluid within the respiratory tract of the affected sheep. Up to 300 mL of lung fluid can be collected by lifting the rear limbs (and thus the chest) above the head of the affected sheep ("wheel-barrow test").
At postmortem examination, the lungs of sheep with OPA are enlarged and the tumor appears as a grayish, firm mass in the cranio-ventral portion of the organ (Fig. 1) the cut surface is generally moist with frothy fluid exuding from the bronchioles of the affected areas. In rare cases, an "atypical" pattern (3335) is observed, with solitary or multiple, hard and dry nodules, usually located in the diaphragmatic lobe. Ultrastructural studies (13,36,37) have shown that the tumor originates from the type II pneumocytes and the nonciliated bronchiolar (Clara) cells. OPA tumor cells maintain the appearance of the cells from which they originated: microvilli, desmosomes, and intracellular lamellar bodies for the type II pneumocytes and cytoplasmic dense bodies for the Clara cells. Both type II pneumocytes and Clara cells are secretory cells. Type II pneumocytes are the sites of synthesis, storage, and secretion of the alveolar surfactant (38,39), whereas Clara cells in the bronchioles are thought to synthesize, store, and secrete protein components of the extracellular lining layer of bronchioles (38,40).
|
Metastases in OPA cases, in both thoracic and extrathoracic tissues, can be observed in some instances (15,4244). In the Awassi sheep of Israel, metastases have been observed in 50% of cases (42). The ability of OPA tumors to metastasize and the capacity to transplant OPA tumor cells and derived cell lines in nude mice (45,46) indicate that the nature of the OPA lesions is neoplastic rather than proliferative, although the majority of OPA lesions show a hyperplastic phenotype.
![]() |
SIMILARITIES BETWEEN OPA AND HUMAN PERIPHERAL ADENOCARCINOMAS |
---|
There are as yet no epidemiologic studies in the literature on bronchioloalveolar carcinoma that take into account the new histologic classification of lung tumors. Various reports are present in the literature based on the old WHO classification (51). Even with the old criteria, the incidence of bronchioloalveolar carcinoma has been debated, and the variability of reports in the literature is probably the result of the above-mentioned difficulty of differentiating bronchioloalveolar carcinoma from other forms of adenocarcinoma (48). A high degree of disagreement around the diagnosis of bronchioloalveolar carcinoma indeed has been reported (55,56). However, the incidence of peripheral adenocarcinomas of all types, including bronchioloalveolar carcinoma, is increasing in the United States and in Japan (5761) and can account for up to a quarter of lung cancers (62). The majority of studies show the incidence of bronchioloalveolar carcinoma to constitute between 1% and 10% of lung cancers (6367), which might be an overestimate if the new classification of lung cancers is taken into account. Bronchioloalveolar carcinoma has some features that might differentiate it from other human lung cancers. Compared with other forms of lung cancer, the incidence of bronchioloalveolar carcinoma is higher in females, in nonsmokers, and in a comparatively young age group (49,50,54,6870). Adenocarcinoma, like any form of lung cancer, is associated with cigarette smoking but less strongly than other lung cancers (69).
OPA has some similarities with bronchioloalveolar carcinoma, or more correctly with peripheral adenocarcinoma, that have been noticed for more than half a century (10,41,47,71). In OPA, like bronchioloalveolar carcinoma and its progressive forms of peripheral adenocarcinoma, the lesions tend to be multifocal and are localized at the periphery of the lungs, and the neoplastic cells are derived from type II pneumocytes and Clara cells. However, from the histopathologic point of view, the somewhat strict current definition of bronchioloalveolar carcinoma does not apply to the histologic appearance of OPA. OPA is rather a mixed adenocarcinoma that grows at the periphery of the lung and shows acinar, papillary, and bronchioloalveolar growth patterns. In addition, the majority of the tumor cells forming OPA lesions do not show malignant characteristics.
From a clinical point of view, it is difficult to compare the disease in sheep and in humans, mainly because OPA in sheep is diagnosed only when the lesions are at an advanced stage resulting in respiratory distress. In humans, bronchioloalveolar carcinoma has been described as having two clinical entities with identical histologic appearance: 1) a focal form with a relatively good prognosis following resection and 2) a multifocal progressive and diffuse form with a worse prognosis regardless of intervention (7275). In sheep, for practical reasons, only the diffuse progressive form is seen because the diagnosis is made only when the affected animal shows evident respiratory distress and, consequently, the tumor is at a late stage.
In conclusion, although there is no perfect animal model for any given human disease, there are enough similarities between OPA and some forms of adenocarcinomas in humans to support the idea that understanding the molecular basis of OPA could provide an intellectual framework to understand some aspects of pulmonary carcinogenesis (see below) (76).
![]() |
JAAGSIEKTE SHEEP RETROVIRUS |
---|
OPA is caused by a retrovirus known as jaagsiekte sheep retrovirus (JSRV). A viral etiology for OPA was suspected beginning in the late 1940s. At that time, OPA was experimentally reproduced by inoculating lambs with a cell-free glycerin solution into which OPA-affected sheep had exhaled (82). In the 1970s and 1980s, the visualization in tumor cells of retrovirus-like particles by electron microscopy studies and the detection in the same materials of reverse transcriptase activity and of polypeptides related immunologically to Mason-Pfizer monkey virus, a simian betaretrovirus, and to mouse mammary tumor virus, a murine betaretrovirus, suggested that a retrovirus was present in OPA (8389). In 1992, the complete genomic sequence of JSRV was determined from a complementary DNA phage library of viral particles RNA purified from lung secretions of an OPA-affected sheep (90,91). The JSRV genome has a simple genetic organization, characteristic of the replication-competent betaretroviruses (92) containing the canonical structural retroviral genes gag, pro, pol, and env (Fig. 2
). An additional open reading frame (orf-x) overlaps pol and has some unusual features, including a codon usage different from that of other genes within JSRV, and a very hydrophobic predicted amino-acid sequence that shows no similarities with any other known protein, with the exception of a low homology to a G-protein-coupled receptor (93,94). The role of this open reading frame is unknown. Although orf-x is conserved among different JSRV isolates (93,94), it does not seem to be required for JSRV replication in vitro (Palmarini M, Fan H: unpublished results) or for cell transformation in vitro (see below) (95).
|
![]() |
MOLECULAR BASIS FOR THE LUNG TROPISM OF JSRV |
---|
|
The tropism of JSRV for differentiated epithelial cells of the lungs is not due to the restricted presence of the viral receptor to these cells. Indeed, JSRV infects cell lines of various tissue origins, also in vitro (106,107). Moreover, as mentioned above, viral DNA can be detected also in lymphoid tissues of JSRV-infected animals. Recently, the cellular receptor for JSRV has been cloned and identified as hyaluronidase-2 (HYAL2), a glycosylphosphatidylinositol-linked cell-surface protein (108). As expected HYAL2 is expressed in many cell types (109,110); therefore, its distribution does not govern the in vivo tropism of JSRV.
On the other hand, the LTR, where the viral promoter and enhancers are located, of JSRV is preferentially active in differentiated epithelial cells of the lungs (111). Our studies employing reporter assays have shown that the JSRV LTR has the highest transcriptional activity in cell lines derived from type II pneumocytes and Clara cells. In addition, the JSRV LTR interacts with transcription factors, such as hepatocyte nuclear factor (HNF)-3, that play a major role in the expression of lung-specific genes, e.g., those of the surfactant proteins (111) (McGee-Estrada K, Palmarini M, Fan H: unpublished results) (112). Thus, the restriction for JSRV expression in type II pneumocytes and Clara cells is due to the preferential activation of the JSRV LTR in these cells.
In the future, the preferential expression of the JSRV LTR for the differentiated lung epithelial cells might be exploited for designing of viral vectors for gene therapy of lung diseases. Efficient transduction and expression in lung cells have proven to be a difficult task with other vectors (113115).
It is interesting that the lung tropism of JSRV was apparently acquired relatively recently in evolutionary terms. The sheep genome contains 1520 copies of endogenous (i.e., transmitted horizontally) retroviruses highly related to JSRV (enJSRVs) (91,116,117), and the estimated time of integration of some of these elements is between 500 000 and 2 million years ago (117,118). enJSRVs are transcriptionally active at a low level in many tissues (119) but are highly expressed in the epithelium of the lumen and the glands of the uterus (118,120). Thus, the ancestor(s) of JSRV were preferentially expressed in the sheep genital tract rather than in the lungs. Indeed, most of the major differences between the exogenous JSRV and its endogenous counterparts are in the U3 region of the LTR, where the viral enhancers are located (118,119,121). In reporter assays, the enJSRV LTRs do not show the high transcriptional specificity for lung epithelial cells that the JSRV LTR does (118). In addition, the enJSRV LTRs do not interact with HNF-3 but do respond to hormonal stimuli such as progesterone (Palmarini M, Murgia C, Spencer T, Fan H: unpublished data).
In one sense, enJSRVs may be indirectly involved in the pathogenesis of OPA. OPA-infected sheep do not show an antibody response toward JSRV (87,122,123). The likely reason is the expression of endogenous elements during fetal development, leading to the tolerance toward the exogenous JSRV. Indeed, in recent studies, we have detected high levels of expression of the enJSRV in the Peyer's patches and gut-associated lymphoid cells of lamb fetuses (Spencer T, Griebel P, Palmarini M: unpublished data).
![]() |
RETROVIRUSES AND CANCER |
---|
The acutely transforming retroviruses are probably among the most powerful carcinogens present in nature. They have captured a cellular proto-oncogene into their genome, altering its structure (deletions, point mutations, etc.) and expression in the process (7880,129,130). Cellular proto-oncogenes are usually conserved over long evolutionary distances, suggesting that they are indispensable for fundamental cellular functions (131). Viral oncogenes work through the synthesis of proteins (oncoproteins) that have the potential to transform a normal cell into a neoplastic one. Most retroviral oncogenes have homology with cellular genes (proto-oncogenes), a hallmark of an oncogene. For example, the avian erythroblastosis virus strain H carries the erbB oncogene that has close homology to the chicken epidermal growth factor receptor (132). As a result of the transduction of the oncogene, the acutely transforming retroviruses typically lack portions of their structural genes and are replication defective. Acutely transforming retroviruses are thus propagated in conjunction with a replication-competent virus called "helper" that encodes all of the viral structural and enzymatic proteins (133135). Viruses containing oncogenes are relatively rare in naturally occurring retrovirus-induced tumors for several reasons: 1) Oncogene capture is an unlikely event, 2) the rapid and lethal course of the induced disease could limit the spread of the infection, and 3) there is probably no evolutionary-positive selection of replication-defective oncogene-containing retroviruses.
The majority of oncogenic retroviruses do not carry an oncogene in their genome (77,104,131,136,137). Such viruses are called "nonacute retroviruses" because the incubation period of the resulting neoplasia is usually several months. Nonacute retroviruses are replication competent. Tumor induction appears to occur through multiple steps, many with similarities to non-virus-induced cancer. The best understood mechanism of nonacute retroviral carcinogenesis is LTR activation of proto-oncogenes, also known as insertional activation, cis-activation, or insertional mutagenesis. In these tumors, a provirus is integrated in the vicinity of a cellular proto-oncogene, resulting in overexpression of the proto-oncogene by one of several mechanisms. Retroviruses that act by insertional activation generally induce tumors with a long incubation period because retroviral integration is essentially a random event with respect to the host DNA (138141). Thus, multiple rounds of infection are typically necessary before integration near (e.g., few to a hundred kilobases) a proto-oncogene occurs in one cell. Under the influence of the viral LTR, the transcription of the proto-oncogene is elevated in that cell and triggers transformation (142146).
Insertional inactivation of tumor suppressor genes in retrovirus-induced tumors is very rare because, unlike proto-oncogenes, the loss of function of a tumor suppressor gene requires that both copies of the gene be damaged or lost. However, the insertional inactivation of one allele could potentiate spontaneous mutations occurring in the other allele, leading to transformation. For instance, the insertional inactivation of p53 has been observed in a proportion of non-B-, non-T-cell lymphomas induced by the Cas-Br-E virus (147).
Other mechanisms involved in retroviral carcinogenesis have been proposed for human T-cell-leukemia virus (HTLV-I) in adult T-cell leukemia (148151) and for bovine leukemia virus (BLV) (152154). Both viruses lack oncogenes and do not show common sites of viral integration in the induced tumors. The tumors are monoclonal or oligoclonal, and viral expression in the tumor cells is minimal (148). The tumors of both humans and cattle appear after a very long incubation period (many years) (155). Besides activating viral transcription, the viral Tax transactivator protein also activates the expression of cellular genes involved in T-cell growth and differentiation, such as interleukin (IL)-2, IL-2 receptor, IL-3, and granulocytemacrophage colony-stimulating factor (156). Many properties of Tax, such as the ability to transform rodent fibroblasts (157) or to be oncogenic when expressed in mice as a transgene (150,158), indicate the oncogenic potential of this gene and of its product. Analogies have been found with the Tax protein of BLV (152). One explanation for HTLV-I leukemogenesis is that the Tax protein leads to hyperproliferation of T lymphocytes, and these cells subsequently progress to end-stage leukemia cells by other spontaneous "hits." This process could explain the very long latency for HTLV-I-induced leukemia as well as the low incidence of leukemia among infected individuals.
![]() |
MECHANISMS OF ONCOGENESIS IN OPA |
---|
Recently, we have carried out experiments that support the notion that JSRV can directly cause tumor formation (95). By performing a standard DNA transfection and cell transformation assay in murine NIH-3T3 cells, we tested the hypothesis that the JSRV genome carries a transforming gene (160). The pCMV2JS21 expression plasmid reproducibly induced foci of transformed cells, whereas control plasmids did not (Fig. 4). When the transformed cells were recovered, they all expressed JSRV RNA. It should be noted that the transformation did not result from spread of infectious virus within the transfected cultures, since murine cells do not have a functional JSRV receptor (107). We carried out further experiments to identify the region of the JSRV genome responsible for transformation. We first asked whether the orf-x region is responsible by specifically mutating it; we found that elimination of the orf-x gene had no effect on the transformation capacity of JSRV. A further deletion in which the gag, pol, and orf-x sequences were deleted (pCMV3JS21deltaGP) also efficiently induced transformed fociin fact, this plasmid reproducibly induced foci more efficiently than pCMV2JS21. These results indicate that the JSRV env gene is capable of inducing transformation of NIH-3T3 cells, and they strongly suggest that this gene is also responsible for the ability of JSRV to cause malignant transformation of lung epithelial cells (95).
|
There are several possible mechanisms by which JSRV envelope protein could transform NIH-3T3 cells. The retroviral envelope is formed by two components: 1) the surface (SU) protein that interacts with the cellular receptor(s) and 2) the transmembrane (TM) protein that fixes the SU into the lipid bilayer. First, it is possible that the SU of the JSRV envelope binds to murine HYAL2 protein (the JSRV receptor) at the cell surface, leading to inhibition of a negative growth-regulatory function of HYAL2. This possibility is exciting because some human lung cancers show loss of heterozygosity (LOH) on the region on human chromosome 3 that contains the HYAL2 gene (3p21.3) (163) (see also below). LOH in tumors is often a signature for loss of a growth-inhibitory (tumor suppressor) gene (164,165). A second possibility is that the SU protein binds to HYAL2 protein at the cell surface, resulting in positive stimulation of cell growth through HYAL2. Even though murine HYAL2 does not function as an efficient receptor for JSRV, it is still possible that envelope protein can bind to murine HYAL2 and affect its function. A third possibility is that the SU protein binds to some other cell surface protein and, in doing so, activates a growth-stimulatory signal. Finally, it is possible that the TM of the JSRV envelope binds to an intracellular protein through its cytoplasmic tail, resulting in activation of a signal cascade. Our latest results favor this last possibility (166). By mutation of a single tyrosine in the cytoplasmic tail of the JSRV TM, we abolished the capacity of the JSRV envelope to transform NIH-3T3 cells. The mutated tyrosine is part of a YXXM motif that is recognized by the phosphatidylinositol 3-kinase (PI-3K). The PI-3K initiates a cell-signaling pathway that appears to inhibit apoptosis and to be required for a number of mitogens during the G1- to S-phase transition of the cell cycle (167). PI-3K activates Akt (also known as protein kinase B). Akt has been shown to have several antiapoptotic properties, one of which is mediated by the phosphorylation and subsequent inactivation of the pro-apoptotic protein BAD (168,169).
We have developed an NIH-3T3-derived cell line (MP1) from a focus of JSRV-transformed cells. MP1 expresses the JSRV envelope. By western blotting analysis, we have detected phosphorylated Akt in MP1 cells but not in the parental NIH-3T3 cells (166). These data strongly point to the cytoplasmic tail of the JSRV transmembrane protein as being important for cell transformation and suggest a new mechanism of retroviral transformation (Fig. 5). Both PI3-K and Akt have been described as oncogenes transduced by retroviruses. In other words, they have been transduced by acutely transforming retroviruses. The catalytic subunit of PI-3K has been transduced by the avian sarcoma virus 16 (170), whereas Akt has been transduced by an ecotropic murine leukemia virus (171,172). In addition, the PI-3K/Akt pathway has recently been found to be involved in the induction of erythropoietin independence of erythroid cells after infection with Friend SFFV (173), further demonstration that the activation of the PI-3K pathway can lead to cell transformation. Indeed, the PI-3K/Akt pathway has been shown to be activated in a number of solid human tumors, including lung cancer (174177). The JSRV envelope needs to be expressed at high levels to be able to transform NIH-3T3 cells. Indeed, transformation is inefficient when the JSRV envelope is under the control of the JSRV LTR, a relatively weak promoter in NIH-3T3 cells (95). The necessity for high levels of virus expression to induce cell transformation in vitro might reflect what happens in JSRV-infected animals. JSRV infects a wide variety of lymphoid tissues and cells (99101), but viral antigen is consistently detected only in differentiated lung epithelial cells (98). Thus, it appears that high levels of viral expression are achieved only in the cells targeted for viral transformation, where the JSRV LTR is specifically active (111).
|
|
![]() |
A RETROVIRUS IN SOME FORMS OF HUMAN ADENOCARCINOMA? |
---|
At the molecular level, several steps forward have been made in understanding the events governing lung carcinogenesis. A detailed analysis of these events is beyond the scope of this review, and the reader is referred to excellent reviews published in recent years on this topic (181183). It is, however, pertinent to mention that one of the most common genetic changes occurring in the pathogenesis of lung cancer is the LOH involving the short arm of chromosome 3 (181). Regions of DNA susceptible to LOH are likely to contain tumor suppressor genes. Homozygous deletions have been found in lung cancer cell lines, uncultured lung tumors, and premalignant lesions in the 3p21.3 region (163,184189). It is interesting that the cellular receptor of JSRV, HYAL2, maps to this region (107); therefore, it is attractive to link, based on this gene, the oncogenesis in OPA with that in some human lung cancers (108). It is difficult, however, to reconcile the putative tumor suppressor activity envisaged for HYAL2 with the activation of the PI-3K/Akt pathway by the cytoplasmic tail of the JSRV ENV. At the moment, we cannot exclude the possibility that HYAL2 is necessary for JSRV oncogenesis, but, if it is, it would appear to favor, rather than to suppress, oncogenesis.
The unique epidemiologic features of bronchioloalveolar carcinoma suggest that the causes of this carcinoma are different from those of other lung malignancies. A possible genetic predisposition to bronchioloalveolar carcinoma has been suggested in some studies, including the almost simultaneous onset of the malignancy in identical twins (67,190,191). Familial predisposition, however, could also be explained by common exposure to carcinogens or infectious agents. A viral etiology for bronchioloalveolar carcinoma has been postulated from time to time (7,8,192194). For instance, the multiclonality of at least some multifocal cases of bronchioloalveolar carcinoma might suggest an environmental carcinogen or an infectious agent (54). Human papillomavirus DNA has been detected in approximately a third of bronchioloalveolar carcinoma cases (n = 22) (193). Of course, the similarities between OPA and bronchioloalveolar carcinoma do not suggest per se a viral etiology for bronchioloalveolar carcinoma. An intriguing finding, however, has been made recently by De las Heras et al. (195). Analysis of 249 human lung tumors by immunohistochemistry employing a rabbit antiserum toward the major capsid protein of JSRV revealed immunoreactive cells in 23% of the cases (Fig. 7). Among others, tumors included 129 bronchioloalveolar carcinomas, 65 adenocarcinomas, and 41 squamous cell carcinomas. Positive samples included 39 (30.2%) of 129 bronchioloalveolar carcinomas and 17 (26.2%) of 65 adenocarcinomas. It is interesting that no positive staining was observed in 51 other lung tumors or in 25 nontumor lesions or normal lung tissues. Thus, the possibility of a JSRV-related retrovirus associated with some form of bronchioloalveolar carcinoma is attractive, although no other virologic or molecular data obtained thus far support this observation. The antigenic positivity observed might simply reflect cross-reaction with the JSRV antiserum of a protein whose expression is increased in the transformed cells. Alternatively, a human endogenous retrovirus (HERV) related immunologically to JSRV might be overexpressed in the neoplastic cells. The expression of some HERVs in human malignancies has been observed, for example, in testicular tumors, but it is not clear if this expression is etiologically related to the tumor (196198).
|
![]() |
CONCLUSIONS |
---|
In relation to human carcinogenesis, research should be directed at testing the hypothesis of the possible involvement of a retrovirus in the etiology of at least some forms of human adenocarcinoma. In any case, the mechanisms of tumorigenesis between OPA and some forms of human adenocarcinomas might have common themes even if they have a different etiology.
![]() |
NOTES |
---|
Supported by Public Health Service grant R01CA82564 (to H. Fan) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services; by a "Wellcome Prize Traveling Research Fellowship"; by an American Cancer Society Ray and Estelle Spehar Fellowship (to M. Palmarini); and by the Cancer Research Institute and the Chao Family Comprehensive Cancer Center of the University of California Irvine and the Veterinary Medical Experiment Station of the University of Georgia.
The recent developments of the OPA/JSRV model would not have happened without the many years of veterinary research conducted by pioneers of this system, such as, among others, Drs. K. Perk (Hebrew University, Jerusalem, Israel), W. B. Martin (Moredun Research Institute, Edinburgh, U.K.), D. W. Verwoerd (Ondersterpoort Veterinary Institute, Ondersterpoort, South Africa), J. M. Sharp (Moredun Research Institute), and many of their colleagues. We are grateful to Drs. Mike Sharp, Cristina Cousens, and Marcelo De las Heras for providing continuous insightful discussion and exchange of reagents and ideas. We also thank the reviewers of this article and Jean-Francois Mornex for their useful comments on human bronchioloalveolar carcinoma.
![]() |
REFERENCES |
---|
1
Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin2000;50:733.
2 Research WCRFAIfC. Food, nutrition and the prevention of cancer: a global perspective. Washington (DC): World Cancer Research Fund/ American Institute for Cancer Research; 1997. p. 37.
3 Parkin DM. The global burden of cancer. Semin Cancer Biol1998;8:21935.[Medline]
4 Surgeon General. Reducing the health consequences of smoking: 25 years of progress. Washington (DC): U.S. Govt Print Off; 1989.
5 Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect1995;103 Suppl 8:13142.[Medline]
6 Greco RJ, Steiner RM, Goldman S, Cotler H, Patchefsky A, Cohn HE. Bronchoalveolar cell carcinoma of the lung. Ann Thorac Surg1986;41:6526.[Abstract]
7 Geddes DM. Bronchioloalveolar carcinoma [editorial]. Br Med J (Clin Res Ed)1987;294:3.
8 Morabia A, Wynder EL. Relation of bronchioloalveolar carcinoma to tobacco. BMJ1992;304:5413.[Medline]
9 Travis WD, Colby TV, Borrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. International histological classification of tumours. 3rd ed. Geneva (Switzerland): World Health Organization; 1999.
10 Perk K, Hod I. Sheep lung carcinoma: an endemic analogue of a sporadic human neoplasm. J Natl Cancer Inst1982;69:7479.[Medline]
11 DeMartini JC, York DF. Retrovirus-associated neoplasms of the respiratory system of sheep and goats. Ovine pulmonary carcinoma and enzootic nasal tumor. Vet Clin North Am Food Anim Pract1997;13:5570.[Medline]
12 Palmarini M, Fan H, Sharp JM. Sheep pulmonary adenomatosis: a unique model of retrovirus-associated lung cancer. Trends Microbiol 1997;5:47883.[Medline]
13 Sharp JM. Sheep pulmonary adenomatosis: a contagious tumour and its cause. Cancer Surv 1987;6:7383.[Medline]
14 Tustin RC. Ovine jaagsiekte. J S Afr Vet Med Assoc 1969;40:323.
15 Verwoerd DW, Tustin RC, Payne AL. Jaagsiekte: an infectious pulmonary adenomatosis of sheep. In: Olsen RG, Krakowaka S, Blackslee JR, editors. Comparative pathobiology of viral diseases. Boca Raton (FL): CRC Press; 1985. p. 5376.
16 Aynaud M. Origin verminouse du cancer pulmonaire de la brebis. Comp Rend Sci Soc Biol 1926;95:15402.
17 Al-Zubaidy A, Sokkar SM. Studies on ovine pulmonary adenomatosis in Iraq. Indian Vet J 1979;56:3602.
18 Ceretto F, Deiand S. Adenomatosi polmonare enzootica degli ovini (jaagsiekte) in Sardegna. Atti della Societá Italiana di Scienze Veterinarie 1967;21:60611.
19 McFadyean J. Verminous pneumonia in the sheep. J Comparative Pathol Ther 1894;7:3142.
20 Stevenson RG, Rehmtulla AJ, Thomson RG. Pulmonary adenomatosis (jaagsiekte) in sheep in Canada [letter]. Can Vet J1980;21:2678.[Medline]
21 Tontis A, Bestetti G, Konig H, Luginbuhl H. Enzootic occurrence of pulmonary adenomatosis in 13 sheep near Bern. Schweiz Arch Tierheilkd 1979;121:25162.[Medline]
22 Toumazos P. First report of sheep pulmonary adenomatosis in Cyprus. Br Vet J 1989;145:28990.[Medline]
23 Eber A. Uber multiple Adenombildung in den Lungen der Shafe. Zeitschrift fuer Tiermedizin 1899;3:16172.
24 Shirlaw JF. Studies on jaagsiekte in Kenya. Bull Epizootic Dis Afr 1959;7:287302.
25 Sigurdsson B. Rida, a chronic encephalitis of sheep: with general remarks on infections which develop slowly and some of their special characteristics. Br Vet J 1954;110:34154.
26
Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998;95:1336383.
27 Chesebro B. Prion protein and the transmissible spongiform encephalopathy diseases. Neuron 1999;24:5036.[Medline]
28 Desrosiers RC, Letvin NL. Animal models for acquired immunodeficiency syndrome. Rev Infect Dis 1987;9:43846.[Medline]
29 Narayan O, Kennedy-Stoskopf S, Zink MC. Lentivirushost interactions: lessons from visna and caprine arthritisencephalitis viruses. Ann Neurol 1988;23 Suppl:S95100.[Medline]
30 Aliev DI. Dynamics of pathomorphological changes in adenomatosis of the lung in sheep. Veterinariia 1967;44:556.
31 Wandera JG. Sheep pulmonary adenomatosis (Jaagsiekte). Adv Vet Sci Comp Med 1971;15:25183.[Medline]
32 Sharp JM, Angus K. Sheep pulmonary adenomatosis: studies on its etiology. In: Petursson G, Hoff-Jogensen R, editors. Maedi-visna and related diseases. Boston (MA): Kluwer Academic Publishers; 1990. p. 17785.
33 Garcia-Goti M, Gonzalez L, Cousens C, Cortabarria N, Extramiana AB, Minguijon E, et al. Sheep pulmonary adenomatosis: characterization of two pathological forms associated with jaagsiekte retrovirus. J Comp Pathol 2000;122:5565.[Medline]
34 De las Heras M, Calafat JJ, Jaime JM, Garcia de Jalon JA, Ferrer LM, Garcia-Goti M, et al. Sheep pulmonary adenomatosis (jaagsiekte) in slaughtered sheep. Variation in pathological characteristics. Med Vet 1992;9(Suppl):523.
35 Gonzales L. El Maedi o pneumonia progresiva en el conjunto de las enfermedales respiratorias cronicas del ganado ovino en la Comunidad Autonoma Vasca. Zaragoza (Spain): Universidad de Zaragoza; 1990.
36 Nisbet DI, Mackay JM, Smith W, Gray EW. Ultrastructure of sheep pulmonary adenomatosis (Jaagsiekte). J Pathol 1971;103:15762.[Medline]
37 Perk K, Hod I, Nobel TA. Pulmonary adenomatosis of sheep (jaagsiekte). I. Ultrastructure of the tumor. J Natl Cancer Inst 1971;46:52537.[Medline]
38 Massaro D. Nonciliated bronchiolar epithelial (Clara) cells. In: Massaro D, editor. Lung cell biology. New York (NY): Marcel Dekker; 1989. p. 81114.
39 Mason RJ, Shannon JM. Alveolar type II pneumocytes. In: Crystal RG, West JB, Weibel ER, Barnes PJ, editors. The lung: scientific foundations. Vol 1. Philadelphia (PA): Lippincott-Raven; 1997. p. 54355.
40 Plopper CG, Dallas MH, Buckpitt AR. Clara cells. In: Crystal RG, West JB, Weibel ER, Barnes PJ, editors. The lung: scientific foundations. Vol 1. Philadelphia (PA): Lippincott-Raven; 1997. p. 51733.
41 Nobel TA, Perk K. Bronchiolo-alveolar cell carcinoma. Animal model: pulmonary adenomatosis of sheep, pulmonary carcinoma of sheep (Jaagsiekte). Am J Pathol 1978;90:7836.[Medline]
42 Nobel TA, Neumann F, Klopfer U. Histological patterns of the metastases in pulmonary adenomatosis of sheep (jaagsiekte). J Comp Pathol 1969;79:53740.[Medline]
43 Hunter AR, Munro R. The diagnosis, occurrence and distribution of sheep pulmonary adenomatosis in Scotland 1975 to 1981. Br Vet J 1983;139:15364.[Medline]
44 Snyder SP, DeMartini JC, Ameghino E, Caletti E. Coexistence of pulmonary adenomatosis and progressive pneumonia in sheep in the central sierra of Peru. Am J Vet Res 1983;44:13348.[Medline]
45 Zimber A, Perk K, Hod I, Irving S, Yegana Y. Heterotransplantation of experimentally induced sheep lung adenomatosis into nude mice. Res Vet Sci 1984;36:1224.[Medline]
46 Jassim FA. Identification and characterization of transformed cells in Jaagsiekte, a contagious lung tumour of sheep. Edinburgh (U.K.): University of Edinburgh; 1988.
47 Bonne C. Morphological resemblance of pulmonary adenomatosis (Jaagsiekte) in sheep and certain cases of cancer of the lung in man. Am J Cancer 1939;35:491501.
48 Edwards CW. Alveolar carcinoma: a review. Thorax 1984;39:16674.[Medline]
49 Schraufnagel D, Peloquin A, Pare JA, Wang NS. Differentiating bronchioloalveolar carcinoma from adenocarcinoma. Am Rev Respir Dis 1982;125:749.[Medline]
50 Liebow A. Bronchiolar-alveolar carcinoma. Adv Intern Med 1960;10:32958.
51 The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol 1982;77:12336.[Medline]
52 Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:284452.[Medline]
53 Manning JT Jr, Spjut HJ, Tschen JA. Bronchioloalveolar carcinoma: the significance of two histopathologic types. Cancer 1984;54:52534.[Medline]
54 Barsky SH, Grossman DA, Ho J, Holmes EC. The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin. Mod Pathol 1994;7:63340.[Medline]
55 Sorensen JB, Hirsch FR, Gazdar A, Olsen JE. Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma. Cancer 1993;71:29716.[Medline]
56 Saleh HA, Haapaniemi J, Khatib G, Sakr W. Bronchioloalveolar carcinoma: diagnostic pitfalls and immunocytochemical contribution. Diagn Cytopathol 1998;18:3016.[Medline]
57 Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996;77:246470.[Medline]
58 Barkley JE, Green MR. Bronchioloalveolar carcinoma. J Clin Oncol 1996;14:237786.[Abstract]
59 Valaitis J, Warren S, Gamble D. Increasing incidence of adenocarcinoma of the lung. Cancer 1981;47:10426.[Medline]
60 Vincent RG, Pickren JW, Lane WW, Bross I, Takita H, Houten L, et al. The changing histopathology of lung cancer: a review of 1682 cases. Cancer 1977;39:164755.[Medline]
61 Auerbach O, Garfinkel L. The changing pattern of lung carcinoma. Cancer 1991;68:19737.[Medline]
62 Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 1994;73:116370.[Medline]
63 Donaldson JC, Kaminsky DB, Elliott RC. Bronchiolar carcinoma: report of 11 cases and review of the literature. Cancer 1978;41:2508.[Medline]
64 Harpole DH, Bigelow C, Young WG Jr, Wolfe WG, Sabiston DC Jr. Alveolar cell carcinoma of the lung: a retrospective analysis of 205 patients. Ann Thorac Surg 1988;46:5027.[Abstract]
65 Epstein DM. Bronchioloalveolar carcinoma. Semin Roentgenol 1990;25:10511.[Medline]
66 Marchetti A, Buttitta F, Pellegrini S, Chella A, Bertacca G, Filardo A, et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996;179:2549.[Medline]
67 Falk RT, Pickle LW, Fontham ET, Greenberg SD, Jacobs HL, Correa P, et al. Epidemiology of bronchioloalveolar carcinoma. Cancer Epidemiol Biomarkers Prev 1992;1:33944.[Abstract]
68 Ives JC, Buffler PA, Greenberg SD. Environmental associations and histopathologic patterns of carcinoma of the lung: the challenge and dilemma in epidemiologic studies. Am Rev Respir Dis 1983;128:195209.[Medline]
69 Fujimoto N, Segawa Y, Takigawa N, Hotta K, Kishino D, Shimono M, et al. Clinical investigation of bronchioloalveolar carcinoma: a retrospective analysis of 53 patients in a single institution. Anticancer Res 1999;19:136973.[Medline]
70 Breathnach OS, Ishibe N, Williams J, Linnoila RI, Caporaso N, Johnson BE. Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer 1999;86:116573.[Medline]
71 Gazdar AF, Linnoila RI. The pathology of lung cancerchanging concepts and newer diagnostic techniques. Semin Oncol 1988;15:21525.[Medline]
72 Miller WT, Husted J, Freiman D, Atkinson B, Pietra GG. Bronchioloalveolar carcinoma: two clinical entities with one pathologic diagnosis. AJR Am J Roentgenol 1978;130:90512.[Medline]
73
Hsu CP, Chen CY, Hsu NY. Bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 1995;110:37481.
74
Dumont P, Gasser B, Rouge C, Massard G, Wihlm JM. Bronchoalveolar carcinoma: histopathologic study of evolution in a series of 105 surgically treated patients. Chest 1998;113:3915.
75
Albertine KH, Steiner RM, Radack DM, Golding DM, Peterson D, Cohn HE, et al. Analysis of cell type and radiographic presentation as predictors of the clinical course of patients with bronchioalveolar cell carcinoma. Chest 1998;113:9971006.
76
Rosenberg N. New transformation tricks from a barnyard retrovirus: implications for human lung cancer. Proc Natl Acad Sci U S A 2001;98:42857.
77 Rosenberg N, Jolicoeur P. Retroviral pathogenesis. In: Coffin JM, Hughes S, Varmus HE, editors. Retroviruses. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. p. 475585.
78 Bishop JM, Varmus HE. Functions and origins of retroviral transforming genes. In: Weiss R, Teich N, Varmus H, Coffin J, editors. RNA tumour viruses. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1984. p. 9991108.
79 Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976;260:1703.[Medline]
80 Stehelin D, Guntaka RV, Varmus HE, Bishop JM. Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses. J Mol Biol 1976;101:34965.[Medline]
81 Vogt PK. Historical introduction to the general properties of retroviruses. In: Coffin JM, editor. Retroviruses. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. p. 125.
82 Dungal N. Experiments with Jaagsiekte. Am J Pathol 1946;22:73759.
83 Martin WB, Scott FM, Sharp JM, Angus KW, Norval M. Experimental production of sheep pulmonary adenomatosis (Jaagsiekte). Nature 1976;264:1835.[Medline]
84 Perk K, Michalides R, Spiegelman S, Schlom J. Biochemical and morphologic evidence for the presence of an RNA tumor virus in pulmonary carcinoma of sheep (Jaagsiekte). J Natl Cancer Inst 1974;53:1315.[Medline]
85 Perk K, Hod I. Demonstration of virus particles in ovine pulmonary adenomata. Experientia 1971;27:4378.[Medline]
86 Bucciarelli E. Pulmonary adenomatosis of the sheep (Jaagsiekte). Ultrastructural study. Lav Ist Anat Istol Patol Univ Studi Perugia 1973;33:99117.[Medline]
87 Sharp JM, Herring AJ. Sheep pulmonary adenomatosis: demonstration of a protein which cross-reacts with the major core proteins of Mason-Pfizer monkey virus and mouse mammary tumour virus. J Gen Virol 1983;64:23237.[Abstract]
88 Herring AJ, Sharp JM, Scott FM, Angus KW. Further evidence for a retrovirus as the aetiological agent of sheep pulmonary adenomatosis (jaagsiekte). Vet Microbiol 1983;8:23749.[Medline]
89 DeMartini JC, Rosadio RH, Sharp JM, Russell HI, Lairmore MD. Experimental coinduction of type D retrovirus-associated pulmonary carcinoma and lentivirus-associated lymphoid interstitial pneumonia in lambs. J Natl Cancer Inst 1987;79:16777.[Medline]
90 York DF, Vigne R, Verwoerd DW, Querat G. Isolation, identification, and partial cDNA cloning of genomic RNA of jaagsiekte retrovirus, the etiological agent of sheep pulmonary adenomatosis. J Virol 1991;65:50617.[Medline]
91 York DF, Vigne R, Verwoerd DW, Querat G. Nucleotide sequence of the jaaksiekte retrovirus, an exogenous and endogenous type D and B retrovirus of sheep and goats. J Virol 1992;66:49309.[Abstract]
92 Hunter E, Casey J, Hahn B, Hayami M, Korber B, Kurth R, et al. The Retroviridae. In: van Regenmortel MH, Fauquet CM, Bishop DH, Carstens EB, Estes MK, Lemon SM, et al, editors. Virus taxonomy. Seven report of the International Committee on Taxonomy of Viruses. San Diego (CA): Academic Press; 2000. p. 36987.
93 Bai J, Bishop JV, Carlson JO, DeMartini JC. Sequence comparison of JSRV with endogenous proviruses: envelope genotypes and a novel ORF with similarity to a G-protein-coupled receptor. Virology 1999;258:33343.[Medline]
94 Rosati S, Pittau M, Alberti A, Pozzi S, York DF, Sharp JM, et al. An accessory open reading frame (orf-x) of jaagsiekte sheep retrovirus is conserved between different virus isolates. Virus Res 2000;66:10916.[Medline]
95
Maeda N, Palmarini M, Murgia C, Fan H. Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA. Proc Natl Acad Sci U S A 2001;98:444954.
96
Palmarini M, Sharp JM, De las Heras M, Fan H. Jaagsiekte sheep retrovirus is necessary and sufficient to induce a contagious lung cancer in sheep. J Virol 1999;73:696472.
97
DeMartini JC, Bishop JV, Allen TE, Jassim FA, Sharp JM, De Las Heras M, et al. Jaagsiekte sheep retrovirus proviral clone JSRV(JS7), derived from the JS7 lung tumor cell line, induces ovine pulmonary carcinoma and is integrated into the surfactant protein A gene. J Virol 2001;75:423946.
98 Palmarini M, Dewar P, De las Heras M, Inglis NF, Dalziel RG, Sharp JM. Epithelial tumour cells in the lungs of sheep with pulmonary adenomatosis are major sites of replication for Jaagsiekte retrovirus. J Gen Virol 1995;76:27317.[Abstract]
99
Holland MJ, Palmarini M, Garcia-Goti M, Gonzalez L, McKendrick I, De las Heras M, et al. Jaagsiekte retrovirus is widely distributed both in T and B lymphocytes and in mononuclear phagocytes of sheep with naturally and experimentally acquired pulmonary adenomatosis. J Virol 1999;73:40048.
100 Palmarini M, Holland MJ, Cousens C, Dalziel RG, Sharp JM. Jaagsiekte retrovirus establishes a disseminated infection of the lymphoid tissues of sheep affected by pulmonary adenomatosis. J Gen Virol 1996;77:29918.[Abstract]
101
Gonzalez L, Garcia-Goti M, Cousens C, Dewar P, Cortabarria N, Extramiana AB, et al. Jaagsiekte sheep retrovirus can be detected in the peripheral blood during the pre-clinical period of sheep pulmonary adenomatosis. J Gen Virol 2001;82:13558.
102 Weiss RA. Retrovirus receptors. Cell 1995;82:5313.[Medline]
103 Athas GB, Starkey CR, Levy LS. Retroviral determinants of leukemogenesis. Crit Rev Oncog 1994;5:16999.[Medline]
104 Fan H. Retroviruses and their role in cancer. In: Levy JA, editor. The Retroviridae. Vol 3. New York (NY): Plenum Press; 1994. p. 31362.
105 Fan H. Influences of the long terminal repeats on retrovirus pathogenicity. Semin Virol 1990;1:16574.
106
Palmarini M, Sharp JM, Lee C, Fan C. In vitro infection of ovine cell lines by Jaagsiekte sheep retrovirus. J Virol 1999;73:100708.
107
Rai SK, DeMartini JC, Miller AD. Retrovirus vectors bearing jaagsiekte sheep retrovirus Env transduce human cells by using a new receptor localized to chromosome 3p21.3. J Virol 2000;74:4698704.
108
Rai SK, Duh FM, Vigdorovich V, Danilkovitch-Miagkova A, Lerman MI, Miller AD. Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc Natl Acad Sci U S A 2001;98:44438.
109
Lepperdinger G, Strobl B, Kreil G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem 1998;273:2246670.
110 Strobl B, Wechselberger C, Beier DR, Lepperdinger G. Structural organization and chromosomal localization of Hyal2, a gene encoding a lysosomal hyaluronidase. Genomics 1998;53:2149.[Medline]
111
Palmarini M, Datta S, Omid R, Murgia C, Fan H. The long terminal repeat of Jaagsiekte sheep retrovirus is preferentially active in differentiated epithelial cells of the lungs. J Virol 2000;74:577687.
112 Whitsett JA, Glasser SW. Regulation of surfactant protein gene transcription. Biochim Biophys Acta 1998;1408:30311.[Medline]
113 Goldman MJ, Lee PS, Yang JS, Wilson JM. Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther 1997;8:22618.[Medline]
114 Grubb BR, Pickles RJ, Ye H, Yankaskas JR, Vick RN, Engelhardt JF, et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994;371:8026.[Medline]
115
Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol 1998;72:601423.
116 Hecht SJ, Carlson JO, DeMartini JC. Analysis of a type D retroviral capsid gene expressed in ovine pulmonary carcinoma and present in both affected and unaffected sheep genomes. Virology 1994;202:4804.[Medline]
117
Hecht SJ, Stedman KE, Carlson JO, DeMartini JC. Distribution of endogenous type B and type D sheep retrovirus sequences in ungulates and other mammals. Proc Natl Acad Sci U S A 1996;93:3297302.
118
Palmarini M, Hallwirth C, York D, Murgia C, de Oliveira T, Spencer T, et al. Molecular cloning and functional analysis of three type D endogenous retroviruses of sheep reveal a different cell tropism from that of the highly related exogenous jaagsiekte sheep retrovirus. J Virol 2000;74:806576.
119 Palmarini M, Cousens C, Dalziel RG, Bai J, Stedman K, DeMartini JC, et al. The exogenous form of Jaagsiekte retrovirus is specifically associated with a contagious lung cancer of sheep. J Virol 1996;70:161823.[Abstract]
120
Spencer TE, Stagg AG, Joyce MM, Jenster G, Wood CG, Bazer FW, et al. Discovery and characterization of endometrial epithelial messenger ribonucleic acids using the ovine uterine gland knockout model. Endocrinology 1999;140:407080.
121 Bai J, Zhu RY, Stedman K, Cousens C, Carlson J, Sharp JM, et al. Unique long terminal repeat U3 sequences distinguish exogenous jaagsiekte sheep retroviruses associated with ovine pulmonary carcinoma from endogenous loci in the sheep genome. J Virol 1996;70:315968.[Abstract]
122 Ortin A, Minguijon E, Dewar P, Garcia M, Ferrer LM, Palmarini M, et al. Lack of a specific immune response against a recombinant capsid protein of Jaagsiekte sheep retrovirus in sheep and goats naturally affected by enzootic nasal tumour or sheep pulmonary adenomatosis. Vet Immunol Immunopathol 1998;61:22937.[Medline]
123 Verwoerd DW, Williamson AL, De Villiers EM. Aetiology of jaagsiekte: transmission by means of subcellular fractions and evidence for the involvement of a retrovirus. Onderstepoort J Vet Res 1980;47:27580.[Medline]
124 Sawyers CL. The bcr-abl gene in chronic myelogenous leukaemia. Cancer Surv 1992;15:3751.[Medline]
125 Rabbitts TH, Boehm T. Structural and functional chimerism results from chromosomal translocation in lymphoid tumors. Adv Immunol 1991;50:11946.[Medline]
126 Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:16584.[Medline]
127 Bos JL. ras oncogenes in human cancer: a review [published erratum appears in Cancer Res 1990;50:1352]. Cancer Res 1989;49:46829.[Abstract]
128 Barbacid M. ras genes. Annu Rev Biochem 1987;56:779827.[Medline]
129 Duesberg PH, Vogt PK. Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc Natl Acad Sci U S A 1970;67:167380.[Abstract]
130 Rasheed S. Retroviruses and oncogenes. In: Levy JA, editor. The Retroviridae. Vol 4. New York (NY): Plenum Press; 1995. p. 293408.
131 Benjamin T, Vogt PK. Cell transformation by viruses. In: Fields BN, Knipe DM, Howley PM, editors. Virology. 2nd ed. New York (NY): Raven Press; 1990. p. 31767.
132 Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307:5217.[Medline]
133 Fung YK, Crittenden LB, Fadly AM, Kung HJ. Tumor induction by direct injection of cloned v-src DNA into chickens. Proc Natl Acad Sci U S A 1983;80:3537.[Abstract]
134 Green PL, Kaehler DA, Risser R. Cell transformation and tumor induction by Abelson murine leukemia virus in the absence of helper virus. Proc Natl Acad Sci U S A 1987;84:59326.[Abstract]
135 Poirier Y, Kozak C, Jolicoeur P. Identification of a common helper provirus integration site in Abelson murine leukemia virus-induced lymphoma DNA. J Virol 1988;62:398592.[Medline]
136 Teich N, Wyke J, Mak T, Bernstein A, Hardy W. Pathogenesis of retrovirus-induced disease. In: Weiss RA, Teich N, Varmus H, Coffin JM, editors. RNA tumor viruses. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1984. p. 25208.
137 Kung HJ, Boerkoel C, Carter TH. Retroviral mutagenesis of cellular oncogenes: a review with insights into the mechanisms of insertional activation. Curr Top Microbiol Immunol 1991;171:125.[Medline]
138 Brown PO. Integration. In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. p. 161203.
139 Brown PO. Integration of retroviral DNA. Curr Top Microbiol Immunol 1990;157:1948.[Medline]
140 Hughes SH, Shank PR, Spector DH, Kung HJ, Bishop JM, Varmus HE, et al. Proviruses of avian sarcoma virus are terminally redundant, co-extensive with unintegrated linear DNA and integrated at many sites. Cell 1978;15:1397410.[Medline]
141 Steffen D, Weinberg RA. The integrated genome of murine leukemia virus. Cell 1978;15:100310.[Medline]
142 Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981;290:47580.[Medline]
143 Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982;31:99109.[Medline]
144 Fung YK, Lewis WG, Crittenden LB, Kung HJ. Activation of the cellular oncogene c-erbB by LTR insertion: molecular basis for induction of erythroblastosis by avian leukosis virus. Cell 1983;33:35768.[Medline]
145 Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984;37:14150.[Medline]
146 Dickson C, Smith R, Brookes S, Peters G. Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell 1984;37:52936.[Medline]
147 Bergeron D, Houde J, Poliquin L, Barbeau B, Rassart E. Expression and DNA rearrangement of proto-oncogenes in Cas-Br-E-induced non-T-, non-B-cell leukemias. Leukemia 1993;7:95462.[Medline]
148 Kinoshita T, Shimoyama M, Tobinai K, Ito M, Ito S, Ikeda S, et al. Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc Natl Acad Sci U S A 1989;86:56204.[Abstract]
149 Matsumoto K, Shibata H, Fujisawa JI, Inoue H, Hakura A, Tsukahara T, et al. Human T-cell leukemia virus type 1 Tax protein transforms rat fibroblasts via two distinct pathways. J Virol 1997;71:444551.[Abstract]
150 Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A 1995;92:105761.[Abstract]
151 Ross TM, Pettiford SM, Green PL. The tax gene of human T-cell leukemia virus type 2 is essential for transformation of human T lymphocytes. J Virol 1996;70:5194202.[Abstract]
152 Kettman R, Burny A, Callebaut I, Droogmans L, Mammerickx M, Willems L, et al. Bovine leukemia virus. In: Levy JA, editor. The Retroviridae. Vol 3. New York (NY): Plenum Press; 1994. p. 3981.
153 Willems L, Grimonpont C, Kerkhofs P, Capiau C, Gheysen D, Conrath K, et al. Phosphorylation of bovine leukemia virus Tax protein is required for in vitro transformation but not for transactivation. Oncogene 1998;16:216576.[Medline]
154 Willems L, Burny A, Collete D, Dangoisse O, Dequiedt F, Gatot JS, et al. Genetic determinants of bovine leukemia virus pathogenesis. AIDS Res Hum Retroviruses 2000;16:178795.[Medline]
155 Sugamura K, Hinuma Y. Human retroviruses: HTLV-I and HTLV-II. In: Levy JA, editor. The Retroviridae. Vol 2. New York (NY): Plenum Press; 1993. p. 399435.
156 Green PL, Chen ISY. Molecular features of the human T-cell leukemia virus. In: Levy JA, editor. The Retroviridae. Vol 4. New York (NY): Plenum Press; 1994. p. 277311.
157 Tanaka A, Takahashi C, Yamaoka S, Nosaka T, Maki M, Hatanaka M. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro.Proc Natl Acad Sci U S A 1990;87:10715.[Abstract]
158 Nerenberg M, Hinrichs SH, Reynolds RK, Khoury G, Jay G. The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. Science 1987;237:13249.[Medline]
159 Sharp JM, Angus KW, Gray EW, Scott FM. Rapid transmission of sheep pulmonary adenomatosis (jaagsiekte) in young lambs. Brief report. Arch Virol 1983;78:8995.[Medline]
160
Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and development into established lines. J Cell Biol 1963;17:299313.
161 Li JP, D'Andrea AD, Lodish HF, Baltimore D. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature 1990;343:7624.[Medline]
162 Alian A, Sela-Donenfeld D, Panet A, Eldor A. Avian hemangioma retrovirus induces cell proliferation via the envelope (env) gene. Virology 2000;276:1618.[Medline]
163 Daly MC, Xiang RH, Buchhagen D, Hensel CH, Garcia DK, Killary AM, et al. A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. Oncogene 1993;8:17219.[Medline]
164 Robertson GP, Huang HJ, Cavenee WK. Identification and validation of tumor suppressor genes. Mol Cell Biol Res Commun 1999;2:110.[Medline]
165
Gray JW, Collins C. Genome changes and gene expression in human solid tumors. Carcinogenesis 2000;21:44352.
166 Palmarini M, Maeda N, Murgia C, De-Fraja C, Hofacre A, Fan H. A phosphatidylinositol-3-kinase (PI-3K) docking site in the cytoplasmic tail of the Jaagsiekte sheep retrovirus transmembrane protein is essential for envelope-induced transformation of NIH3T3. J Virol. In press 2001.
167 Roche S, Koegl M, Courtneidge SA. The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors. Proc Natl Acad Sci U S A 1994;91:91859.[Abstract]
168
Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:290527.
169
Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997;275:6615.
170
Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997;276:184850.
171 Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991;254:2747.[Medline]
172 Staal SP, Hartley JW, Rowe WP. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci U S A 1977;74:30657.[Abstract]
173
Nishigaki K, Hanson C, Ohashi T, Thompson D, Muszynski K, Ruscetti S. Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins. J Virol 2000;74:303745.
174
Kobayashi M, Nagata S, Iwasaki T, Yanagihara K, Saitoh I, Karouji Y, et al. Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 1999;96:48749.
175 Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 1998;58:523947.[Abstract]
176 Phillips WA, St Clair F, Munday AD, Thomas RJ, Mitchell CA. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer 1998;83:417.[Medline]
177 Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99102.[Medline]
178 White MK, Strayer DS. Surfactant protein A regulates pulmonary surfactant secretion via activation of phosphatidylinositol 3-kinase in type II alveolar cells. Exp Cell Res 2000;255:6776.[Medline]
179 Strayer DS, Korutla L. Activation of surfactant protein-B transcription: signaling through the SP-A receptor utilizing the PI3 kinase pathway. J Cell Physiol 2000;184:22938.[Medline]
180 Baron J, Ronan T. Tobacco. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. New York (NY): Oxford University Press; 1996. p. 26989.
181 Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998;1378:F2159.[Medline]
182
Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999;118:113652.
183 Forgacs E, Zochbauer-Muller S, Olah E, Minna JD. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 2001;7:613.[Medline]
184 Kok K, van den Berg A, Veldhuis PM, van der Veen AY, Franke M, Schoenmakers EF, et al. A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. Cancer Res 1994;54:41837.[Abstract]
185 Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, et al. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 1996;12:128997.[Medline]
186 Todd S, Franklin WA, Varella-Garcia M, Kennedy T, Hilliker CE Jr, Hahner L, et al. Homozygous deletions of human chromosome 3p in lung tumors. Cancer Res 1997;57:134452.[Abstract]
187 Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD, et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 1995;273:55863.[Abstract]
188 Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 1992;7:198997.[Medline]
189 Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999;18:64350.[Medline]
190 Paul SM, Bacharach B, Goepp C. A genetic influence on alveolar cell carcinoma. J Surg Oncol 1987;36:24952.[Medline]
191 Joishy SK, Cooper RA, Rowley PT. Alveolar cell carcinoma in identical twins. Similarity in time of onset, histochemistry, and site of metastasis. Ann Intern Med 1977;87:44750.[Medline]
192 Peterschmitt AM, Moro DG, Perron HJ, Brambilla EM. Bronchoalveolar carcinoma, lymphoid interstitial pneumonia, and retroviruses [letter]. Clin Infect Dis 1994;19:11789.[Medline]
193 Nuorva K, Soini Y, Kamel D, Pollanen R, Bloigu R, Vahakangas K, et al. p53 protein accumulation and the presence of human papillomavirus DNA in bronchiolo-alveolar carcinoma correlate with poor prognosis. Int J Cancer 1995;64:4249.[Medline]
194 Stinson JC, Leibovitz A, Brindley GV Jr, Hayward RH, Turner RA, McCombs WB 3rd . Filamentous particles in human alveolar cell carcinomas: electron microscopy studies of six cases (preliminary report). J Natl Cancer Inst 1972;49:148393.[Medline]
195
De las Heras M, Barsky SH, Hasleton P, Wagner M, Larson E, Egan J, et al. Evidence for a protein related immunologically to the jaagsiekte sheep retrovirus in some human lung tumours. Eur Respir J 2000;16:3302.
196 Sauter M, Schommer S, Kremmer E, Remberger K, Dolken G, Lemm I, et al. Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J Virol 1995;69:41421.[Abstract]
197
Lower R, Lower J, Kurth R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci U S A 1996;93:517784.
198 Tonjes RR, Lower R, Boller K, Denner J, Hasenmaier B, Kirsch H, et al. HERV-K: the biologically most active human endogenous retrovirus family. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S2617.[Medline]
Manuscript received June 8, 2001; revised August 24, 2001; accepted September 25, 2001.
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |